Category: clinical study retractions

Reverse peristalsis for gut journal which disgorges Cleveland Clinic paper for plagiarism

ajg_cimageThe American Journal of Gastroenterology has retracted a 2011 article on colon cancer by a group of Cleveland Clinic researchers after finding “evidence” of plagiarism in the text.

The article, a review, was titled “Molecular Pathways Underlying IBD-Associated Colorectal Neoplasia: Therapeutic Implications,” and has been cited 16 times, according to Thomson Scientific’s Web of Knowledge.

Here’s the retraction notice: Continue reading Reverse peristalsis for gut journal which disgorges Cleveland Clinic paper for plagiarism

Senator “unsatisfied” with ORI’s response on recovery of tainted grant money

ori logoMarch has come in like a lion for the folks at the Office of Research Integrity (ORI).

The agency’s director, David Wright, stepped down late last month for reasons that even now remain unclear. And in what seems to be an unrelated development, ORI has managed to draw the ire of Sen. Charles Grassley, who has been among the staunchest watchdogs over federal research integrity.

According to the Des Moines Register, the Iowa Republican

Continue reading Senator “unsatisfied” with ORI’s response on recovery of tainted grant money

Not-so-tiny ethics issues as Micron retracts first-ever paper, and authors apologize for five duplicates

micronThe editors of the journal Micron — an Elsevier title — have retracted its first paper ever, and in an editorial marking the occasion, take on a number of issues in scientific publishing misconduct.

The beginning of the editorial (which is paywalled): Continue reading Not-so-tiny ethics issues as Micron retracts first-ever paper, and authors apologize for five duplicates

Penkowa-Pedersen paper retracted nearly three years after being subjected to Notice of Concern

faseb journalWe have an update on the complicated story of Milena Penkowa and Bente Klarlund Pedersen.

Two papers coauthored by the pair — who have both been found guilty of scientific dishonesty by the Danish Committees on Scientific Dishonesty — have been retracted by the FASEB Journal.

Here’s one notice (both are unfortunately behind a paywall): Continue reading Penkowa-Pedersen paper retracted nearly three years after being subjected to Notice of Concern

Hip disjoint: Dysplasia paper lacks proper attribution, earns retraction

ajhbcoverA suggestion: When you title your paper “Joined at the hip?”, better make sure it’s not too close for comfort to someone else’s work.

Alas, an Idaho anthropologist failed to heed that lesson when she published “Joined at the hip? A paleoepidemiological study of developmental dysplasia of the hip and its relation to swaddling practices among indigenous peoples of North America,” in the American Journal of Human Biology last October.

The article, by Samantha Blatt, of Boise State University, found that: Continue reading Hip disjoint: Dysplasia paper lacks proper attribution, earns retraction

“Knowledgeable informant” topples ovarian cancer paper

ijcepA group of cancer researchers in China has lost their 2013 paper in the International Journal of Clinical and Experimental Pathology after someone tipped off the journal that the data were copied.

The article, “Importance of spondin 1 and cellular retinoic acid binding protein 1 in the clinical diagnosis of ovarian cancer,” came from Ting-Ting Jiao, Ye-Min Zhang, Lin Yao, Yuan Gao, Jian Sun, Dong-Fang Zou, Guo-Ping Wu, Dan Wang, Jun Ou, Ning Hui, who work at various Shanghai hospitals.

Here’s the retraction notice: Continue reading “Knowledgeable informant” topples ovarian cancer paper

Pharmaceutical journal retracts antibiotics paper with dodgy data, with an unclear notice

aapsAAPS PharmSciTech, a journal of the American Association of Pharmaceutical Scientists, has retracted a 2013 paper by a group from India. The reason appears to be manipulated data, although the wording of the notice leaves that open to interpretation.

The article, “Design and Formulation Technique of a Novel Drug Delivery System for Azithromycin and Its Anti-Bacterial Activity Against Staphylococcus aureus,” was written by a trio of researchers at the Center for Nanobiotechnology at VIT University in Vellore.

The article, published online in June, purported to find that: Continue reading Pharmaceutical journal retracts antibiotics paper with dodgy data, with an unclear notice

“Protracted and unresolved authors dispute” and “striking similarities” lead to two retractions

panafmedjrIt’s been a busy month for retractions at the Pan African Medical Journal (PAMJ) — dedicated to “Better health through knowledge sharing and information dissemination.”

The journal has retracted a 2013 article by a group from Bangalore, India, for plagiarism. And unlike the authors, the editors didn’t mince words.

The paper, “Detection of ESBL among ampc producing enterobacteriaceae using inhibitor-based method,” concluded that: Continue reading “Protracted and unresolved authors dispute” and “striking similarities” lead to two retractions

Immunology researcher with Expression of Concern has cluster of recent retractions, corrections

j heart lung transplantXia Jiahong, an immunology researcher at Huazhong Science and Technology University in Wuhan, China, who had a paper subject to a fascinating Expression of Concern earlier this month, turns out to have had a few other entries in his retraction and correction record recently.

Here’s a retraction in the January 2014 issue of the Journal of Heart and Lung Transplantation, for “Combined treatment with chemokine receptor 5 blocker and cyclosporine induces prolonged graft survival in a mouse model of cardiac transplantation,” a paper first published in 2010: Continue reading Immunology researcher with Expression of Concern has cluster of recent retractions, corrections

IRB mishap costs MD Anderson team a paper on prostate cancer

bjuifeb14A group of researchers from MD Anderson Cancer Center in Houston has lost a 2013 paper in BJU International for running afoul of their institution’s ethics review board, and of military reviewers, as well.

The paper, “Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance,” looked at prostate cancer screening in men 55 and under — considered young for the older-man’s disease. According to the abstract: Continue reading IRB mishap costs MD Anderson team a paper on prostate cancer